# Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

> **NCT07311369** · PHASE2 · RECRUITING · sponsor: **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Moderate to Severe Acute Postoperative Pain

## Interventions

- **DRUG:** HL-1186
- **DRUG:** HL-1186 placebo

## Key facts

- **NCT ID:** NCT07311369
- **Lead sponsor:** Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-02
- **Final completion:** 2026-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311369, "Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07311369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*